Prodigiosin-induced cytotoxicity involves RAD51 down-regulation through the JNK and p38 MAPK pathways in human breast carcinoma cell lines

Toxicology Letters

Volumn 212, Issue 1, 2012, Pages 83-89

  Lu, Chien Hsing ^a,b,c   Lin, Shin Chang ^a   Yang, Shu Yi ^a   Pan, Mu Yun ^a   Lin, Yun Wei ^d   Hsu, Chun Yi ^a   Wei, Yu Hong ^e   Chang, Jo Shu ^f   Chang, Chia Che ^a,g  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^e YUAN ZE UNIVERSITY   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; DNA double strand breaks; Homologous recombination repair pathway; Prodigiosin; RAD51

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PRODIGIOSIN; PROTEIN P53; RAD51 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; BREAST CARCINOMA; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; IMMUNOBLOTTING; MAP KINASE KINASE 4; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PRODIGIOSIN; RAD51 RECOMBINASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

BACTERIA (MICROORGANISMS); MAMMALIA;

EID: 84861477219     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.05.002     Document Type: Article

References (29)

1. Ambrosini G., Seelman S.L., Qin L.X., Schwartz G.K. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Research 2008, 68:2312-2320.
2. Arias-Lopez C., Lazaro-Trueba I., Kerr P., Lord C.J., Dexter T., Iravani M., Ashworth A., Silva A. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Reports 2006, 7:219-224.
3. Chang C.C., Chen W.C., Ho T.F., Wu H.S., Wei Y.H. Development of natural anti-tumor drugs by microorganisms. Journal of Bioscience and Bioengineering 2011, 111:501-511.
4. Chen R.S., Jhan J.Y., Su Y.J., Lee W.T., Cheng C.M., Ciou S.C., Lin S.T., Chuang S.M., Ko J.C., Lin Y.W. Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Experimental Cell Research 2009, 315:2658-2672.
5. Espona-Fiedler M., Soto-Cerrato V., Hosseini A., Lizcano J.M., Guallar V., Quesada R., Gao T., Pérez-Tomás R. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax. Biochemical Pharmacology 2012, 83:489-496.
6. Fan M., Chambers T.C. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resistance Updates 2001, 5:253-267.
7. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2008, 127:2893-2917.
8. Ho T.F., Ma C.J., Lu C.H., Tsai Y.T., Wei Y.H., Chang J.S., Lai J.K., Cheuh P.J., Yeh C.T., Tang P.C., Tsai-Chang J., Ko J.L., Liu F.S., Yen H.E., Chang C.C. Undecylprodigiosin selectively induces apoptosis in human breast carcinoma cells independent of p53. Toxicology and Applied Pharmacology 2007, 225:318-328.
9. Ho T.F., Peng Y.T., Chuang S.M., Lin S.C., Feng B.L., Lu C.H., Yu W.J., Chang J.S., Chang C.C. Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines. Toxicology and Applied Pharmacology 2009, 235:253-260.
10. Hsieh H.Y., Shieh J.J., Chen C.J., Pan M.Y., Yang S.Y., Lin S.C., Chang J.S., Lee A.Y., Chang C.C. Prodigiosin down-regulates SKP2 to induce p27KIP1 stabilization and antiproliferation in human lung adenocarcinoma cells. British Journal of Pharmacology 2012, http://dx.doi.org/10.1111/j.1476-5381.2012.01921.x.
11. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61:69-90.
12. Klein H.L. The consequence of Rad51 overexpression for normal and tumor cells. DNA Repair (Amsterdam) 2010, 7:686-693.
13. Ko J.C., Ciou S.C., Cheng C.M., Wang L.H., Hong J.H., Jheng M.Y., Ling S.T., Lin Y.W. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis 2008, 29:1448-1458.
14. Ko J.C., Hong J.H., Wang L.H., Cheng C.M., Ciou S.C., Lin S.T., Jheng M.Y., Lin Y.W. Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Molecular Cancer Therapeutics 2008, 7:3632-3641.
15. Ko J.C., Su Y.J., Lin S.T., Jhan J.Y., Ciou S.C., Cheng C.M., Lin Y.W. Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochemical Pharmacology 2010, 79:655-664.
16. Ko J.C., Tsai M.S., Weng S.H., Kuo Y.H., Chiu Y.F., Lin Y.W. Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicology and Applied Pharmacology 2011, 255:327-338.
17. Montaner B., Castillo-Avila W., Martinell M., Ollinger R., Aymami J., Giralt E., Pérez-Tomás R. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin. Toxicological Sciences 2005, 85:870-879.
18. Montaner B., Pérez-Tomás R. The cytotoxic prodigiosin induces phosphorylation of p38-MAPK but not of SAPK/JNK. Toxicology Letters 2002, 129:93-98.
19. NCCN clinical practice guidelines in oncology. Breast Cancer. 2nd ed., 2011. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
20. NCI, 2008. Available at: http://seer.cancer.gov/statfacts/html/breast.html.
21. Pandey R., Chander R., Sainis K.B. Prodigiosins as anti-cancer agents: living up to their name. Current Pharmaceutical Design 2009, 15:732-741.
22. Pérez-Tomás R., Viñas M. New insights on the antitumoral properties of prodiginines. Current Medicinal Chemistry 2010, 17:2222-2231.
23. Powell S.N., Kachnic L.A. Therapeutic exploitation of tumor cell defects in homologous recombination. Anti-Cancer Agent Medical Chemistry 2008, 8:448-460.
24. Ralhan R., Kaur J., Kreienberg R., Wiesmüller L. Links between DNA double strand break repair and breast cancer. Accumulating evidence from both familial and nonfamilial cases. Cancer Letters 2007, 248:1-17.
25. Schild D., Wiese C. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Research 2010, 38:1061-1070.
26. Soto-Cerrato V., Viñals F., Lambert J.R., Kelly J.A., Pérez-Tomás R. Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells. Molecular Cancer Therapeutics 2007, 6:362-369.
27. WAF1/CIP1 expression via transforming growth factor-beta receptor pathway. Biochemical Pharmacology 2007, 4:1340-1349.
28. Tsai M.S., Kuo Y.H., Chiu Y.F., Su Y.C., Lin Y.W. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. Journal of Pharmacology and Experimental Therapeutics 2010, 335:830-840.
29. Walsh T., King M.C. Ten genes for inherited breast cancer. Cancer Cell 2007, 11:103-105.